Key Points
- COO Jim Wassil sold 2,250 Vaxcyte shares on May 1 at an average price of $56.83 for $127,867.50 under a pre-arranged Rule 10b5-1 plan, leaving him with 160,744 shares (a 1.38% ownership decrease).
- Vaxcyte reported quarterly EPS of ($1.80), missing estimates of ($1.46); analysts hold a consensus "Moderate Buy" rating with an average price target of $86.00.
- Wassil also sold 7,395 shares on March 10 at $58.88, marking multiple insider sales this year while the stock trades in a one‑year range of $28.09–$65.00.
Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) COO Jim Wassil sold 2,250 shares of the company's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $56.83, for a total transaction of $127,867.50. Following the completion of the transaction, the chief operating officer directly owned 160,744 shares of the company's stock, valued at approximately $9,135,081.52. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jim Wassil also recently made the following trade(s):
- On Tuesday, March 10th, Jim Wassil sold 7,395 shares of Vaxcyte stock. The shares were sold at an average price of $58.88, for a total transaction of $435,417.60.
Vaxcyte Price Performance
NASDAQ:PCVX opened at $56.93 on Friday. The firm has a 50-day moving average of $58.73 and a two-hundred day moving average of $51.47. The stock has a market cap of $8.22 billion, a P/E ratio of -10.13 and a beta of 1.30. Vaxcyte, Inc. has a 1-year low of $28.09 and a 1-year high of $65.00.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($1.80) earnings per share for the quarter, missing analysts' consensus estimates of ($1.46) by ($0.34). During the same quarter in the prior year, the firm earned ($1.12) EPS. As a group, equities analysts expect that Vaxcyte, Inc. will post -7 earnings per share for the current year.
Hedge Funds Weigh In On Vaxcyte
Several large investors have recently modified their holdings of PCVX. Smartleaf Asset Management LLC lifted its position in shares of Vaxcyte by 156.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company's stock worth $27,000 after purchasing an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company's stock worth $30,000 after purchasing an additional 600 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company's stock worth $34,000 after purchasing an additional 184 shares during the last quarter. Allworth Financial LP lifted its position in shares of Vaxcyte by 148.9% during the third quarter. Allworth Financial LP now owns 1,222 shares of the company's stock worth $44,000 after purchasing an additional 731 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Vaxcyte during the third quarter worth about $45,000. Institutional investors own 96.78% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on PCVX. Guggenheim reissued a "buy" rating and issued a $116.00 price objective on shares of Vaxcyte in a research report on Monday, February 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Vaxcyte in a research report on Wednesday, April 8th. Needham & Company LLC upped their target price on shares of Vaxcyte from $90.00 to $110.00 and gave the company a "buy" rating in a research note on Wednesday, January 7th. Wall Street Zen cut shares of Vaxcyte from a "sell" rating to a "strong sell" rating in a research report on Tuesday. Finally, Jefferies Financial Group reaffirmed a "buy" rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Vaxcyte presently has a consensus rating of "Moderate Buy" and an average target price of $86.00.
Check Out Our Latest Analysis on PCVX
About Vaxcyte
(
Get Free Report)
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
